Paper41999993
From legacy to innovation: A comprehensive review of vaccine platforms against viral infections.
Farsiu N and 8 others. Virus Res, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. From legacy to innovation: A comprehensive review of vaccine platforms against viral infections. Papers, record 41999993. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41999993
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- From legacy to innovation: A comprehensive review of vaccine platforms against viral infections.
- PubMed
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Virus Diseases | Major topic |
| Vaccine Development | Major topic |
| Viral Vaccines | Major topic |
| Humans | |
| Vaccines, Virus-Like Particle | |
| Animals | |
| Vaccines, DNA | |
| Vaccination | |
| COVID-19 | |
| COVID-19 Vaccines | |
| Vaccines, Subunit | |
| Vaccines, Attenuated | |
| Vaccine Efficacy |
Source PubMed
References105
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 35231177 | Current Developments and Challenges of mRNA Vaccines. | Annu Rev Biomed Eng | 2022 | https://conductscience.org/library/papers/35231177 | PubMed |
| 2 | 28778817 | Production of virus-like particles for vaccines. | N Biotechnol | 2017 | https://conductscience.org/library/papers/28778817 | PubMed |
| 3 | 39772007 | Vaccine Strategies Against RNA Viruses: Current Advances and Future Directions. | Vaccines (Basel) | 2024 | https://conductscience.org/library/papers/39772007 | PubMed |
| 4 | 31477918 | A protective Zika virus E-dimer-based subunit vaccine engineered to abrogate antibody-dependent enhancement of dengue infection. | Nat Immunol | 2019 | https://conductscience.org/library/papers/31477918 | PubMed |
| 5 | 37896820 | Exploring the Potential of Cytomegalovirus-Based Vectors: A Review. | Viruses | 2023 | https://conductscience.org/library/papers/37896820 | PubMed |
| 6 | 36184873 | Nanovaccines to combat virus-related diseases. | Wiley Interdiscip Rev Nanomed Nanobiotechnol | 2023 | https://conductscience.org/library/papers/36184873 | PubMed |
| 7 | 40896582 | Thermostable unit solid dose formulations for subcutaneous administration of DNA vaccines. | Mol Ther Nucleic Acids | 2025 | https://conductscience.org/library/papers/40896582 | PubMed |
| 8 | 37797831 | DNA Vaccines: History, Molecular Mechanisms and Future Perspectives. | J Mol Biol | 2023 | https://conductscience.org/library/papers/37797831 | PubMed |
| 9 | 38140619 | Evolving Horizons: Adenovirus Vectors' Timeless Influence on Cancer, Gene Therapy and Vaccines. | Viruses | 2023 | https://conductscience.org/library/papers/38140619 | PubMed |
| 10 | 32392457 | Challenges of Making Effective Influenza Vaccines. | Annu Rev Virol | 2020 | https://conductscience.org/library/papers/32392457 | PubMed |
| 11 | 37029123 | Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases. | Signal Transduct Target Ther | 2023 | https://conductscience.org/library/papers/37029123 | PubMed |
| 12 | 39433939 | Advanced technologies for the development of infectious disease vaccines. | Nat Rev Drug Discov | 2024 | https://conductscience.org/library/papers/39433939 | PubMed |
| 13 | 40573919 | Next-Generation Vaccine Platforms: Integrating Synthetic Biology, Nanotechnology, and Systems Immunology for Improved Immunogenicity. | Vaccines (Basel) | 2025 | https://conductscience.org/library/papers/40573919 | PubMed |
| 14 | 30765167 | Inactivated or damaged? Comparing the effect of inactivation methods on influenza virions to optimize vaccine production. | Vaccine | 2019 | https://conductscience.org/library/papers/30765167 | PubMed |
| 15 | 32407708 | The Challenges of Vaccine Development against a New Virus during a Pandemic. | Cell Host Microbe | 2020 | https://conductscience.org/library/papers/32407708 | PubMed |
| 16 | 37168860 | mRNA vaccines: a new opportunity for malaria, tuberculosis and HIV. | Front Immunol | 2023 | https://conductscience.org/library/papers/37168860 | PubMed |
| 17 | 34023496 | Drug combination therapy for emerging viral diseases. | Drug Discov Today | 2021 | https://conductscience.org/library/papers/34023496 | PubMed |
| 18 | 32514646 | Epstein-Barr virus-associated gastric cancer: disease that requires special approach. | Gastric Cancer | 2020 | https://conductscience.org/library/papers/32514646 | PubMed |
| 19 | 32878891 | Structure-Based Design of Hepatitis C Virus E2 Glycoprotein Improves Serum Binding and Cross-Neutralization. | J Virol | 2020 | https://conductscience.org/library/papers/32878891 | PubMed |
| 20 | 37632102 | Vaccines' New Era-RNA Vaccine. | Viruses | 2023 | https://conductscience.org/library/papers/37632102 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41999993
GET https://conductscience.org/api/papers/v1/41999993/references?page=2